Bellicum to Report Second Quarter 2020 Financial Results and Provide Corporate Update
30 juil. 2020 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will...
Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors
15 juin 2020 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, June 15, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced clearance by...